Mucositis

  • Noor Al-Dasooqi
  • Dorothy M. Keefe
  • Dorothy M. Keefe
  • Stephen T. Sonis
Chapter

Abstract

Alimentary tract (AT) mucositis is a serious and debilitating side effect of cancer therapy, primarily characterised by damage to the mucous membranes throughout the AT, and associated with mouth ulcers and pain, vomiting, diarrhoea, rectal bleeding and abdominal cramps to name a few. Considerable progress has been made in our understanding of the biological basis for mucositis, and the ­understanding of pathobiology continues to evolve. In recent years, the biggest advance has come from the 5-phase model of mucositis development. The main pathobiological features of mucositis include changes to tissue structure, and surface area, microbiome changes and inflammation. With a better understanding of mucositis pathogenesis, the focus of more recent research is shifting to targeted therapy-induced toxicity, toxicity clustering and the investigation of genetic polymorphisms in toxicity prediction. The ultimate goal of mucositis researchers is to identify the most appropriate targets for therapeutic interventions and to be able to predict toxicity risk and personalise interventions to genetically suitable patients. Continuing research efforts are needed to further our understanding of mucositis pathobiology and the pharmacogenomics of toxicity. This book chapter will update our understanding of the recent concepts of mucositis pathogenesis.

Keywords

Fatigue Paclitaxel Folate Neutropenia Lactose 

References

  1. 1.
    Al-Dasooqi N, Bowen J, Gibson R, Logan R, Stringer A, Keefe D. Irinotecan-induced alterations in intestinal cell kinetics and extracellular matrix component expression in the dark agouti rat. Int J Exp Pathol. 2011;92:357–65.PubMedGoogle Scholar
  2. 2.
    Al-Dasooqi N, Bowen J, Gibson R, Sullivan T, Lees J, Keefe D. Trastuzumab induces gastrointestinal side effects in HER2-overexpressing breast cancer patients. Invest New Drugs. 2008;27:173–8.PubMedGoogle Scholar
  3. 3.
    Al-Dasooqi N, Gibson R, Bowen J, Logan R, Stringer A, Keefe D. Matrix metalloproteinases are possible mediators for the development of alimentary tract mucositis in the DA rat. Exp Biol Med. 2010;235:1244–56.Google Scholar
  4. 4.
    Andreyev H. Gastrointestinal symptoms after pelvic radiotherapy: a new understanding to improve management of symptomatic patients. Lancet Oncol. 2005;8:1007–17.Google Scholar
  5. 5.
    Aprile G, Ramoni M, Keefe DM, Sonis S. Application of distance matrices to define associations between acute toxicities in colorectal cancer patients receiving chemotherapy. Cancer. 2008;112:284–92.PubMedGoogle Scholar
  6. 6.
    Bach SP, Renehan AG, Potten CS. Stem cells: the intestinal stem cell as a paradigm. Carcinogenesis. 2000;21(3):469.PubMedGoogle Scholar
  7. 7.
    Bahri S, Agarwala S, Cano E, Johnson J, Myers E, Jeong J. Phase II study of weekly carboplatin and paclitaxel concurrent with radiation therapy (RT) in patients with locally advanced, inoperable squamous cell carcinoma of the head and neck (HNSCC) [abstract 1667]. Prog/Proc Am Soc Clin Oncol. 2000;19:422a.Google Scholar
  8. 8.
    Bartsch R, Wenzel C, Altorjai G, Pluschnig U, Rudas M, Mader R, et al. Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol. 2007;25:3853–8.PubMedGoogle Scholar
  9. 9.
    Baselga J. Clinical trials of single-agent trastuzumab (Herceptin). Semin Oncol. 2000;27(5 Suppl 9):20–6.PubMedGoogle Scholar
  10. 10.
    Baselga J. Clinical trials of Herceptin (Trastuzumab). Eur J Cancer. 2001;37:18–24.PubMedGoogle Scholar
  11. 11.
    Beck P, Wong J, Li Y, Swaminthan S, Xavier R, Devaney K, et al. Chemotherapy- and radiotherapy-induced intestinal damage is regulated by intestinal trefoil factor. Gastroenterology. 2004;126:796–808.PubMedGoogle Scholar
  12. 12.
    Begg A, Stewart F, Vens C. Strategies to improve radiotherapy with targeted drugs. Nat Rev Cancer. 2011;11:239–53.PubMedGoogle Scholar
  13. 13.
    Belkacemi Y, Gligorov J, Ozsahin M, Marsiglia H, De Lafontan B, Laharie-Mineur H, et al. Concurrent trastuzumab with adjuvant radiotherapy in HER2-positive breast cancer patients: acute toxicity analyses from the French multicentric study. Ann Oncol. 2008;19(6):1110–6.PubMedGoogle Scholar
  14. 14.
    Blijlevens N, Donnelly J. Mucosal barrier injury and infections. Principles and Practice of Cancer Infectious Diseases, Current Clinical Oncology. S. A, Springer Science; 2011.Google Scholar
  15. 15.
    Bloomer W, Hellman S. Normal tissue responses to radiation therapy. New Engl J Med. 1975;293:80–3.PubMedGoogle Scholar
  16. 16.
    Bochud P, Eggiman CT, Van Melle G, Saghafi L, Francioli P. Bacteremia due to viridans streptococcus in neutropenic patients with cancer: clinical spectrum and risk factors. Clin Infect Dis. 1994;18:25–31.PubMedGoogle Scholar
  17. 17.
    Booth D, Potten C. Protection against mucosal injury by growth factors and cytokines. J Natl Cancer Inst. 2001;29:16–20.Google Scholar
  18. 18.
    Bowen J, Gibson R, Cummins A, Keefe D. Intestinal mucositis: the role of the Bcl-2 family, p53 and caspases in chemotherapy-induced damage. Support Care Cancer. 2006;14:713–31.PubMedGoogle Scholar
  19. 19.
    Bowen J, Gibson R, Keefe D, Cummins A. Cytotoxic chemotherapy up-regulates pro-apoptotic Bax and Bak in the small intestine of rats and humans. Pathology. 2005;37:56–62.PubMedGoogle Scholar
  20. 20.
    Buccheri G, Ferrigno D, Rosso A. A phase II study of methotrexate, doxorubicin, cyclophosphamide, and lomustine chemotherapy in advanced non-small cell lung cancer. Cancer. 1993;72:1564–72.PubMedGoogle Scholar
  21. 21.
    Bultzingslowen I, Brennan M, Spijkervet F, Logan R, Stringer A, Raber-Durlacker J, et al. Growth factors and cytokines in the prevention and treatment of oral and gastrointestinal mucositis. Support Care Cancer. 2006;14:519–27.Google Scholar
  22. 22.
    Burkitt HG, Young B, Heath JW. Oral Tissues. In: Burkitt HG, Young B, Heath JW, editors. Wheater’s functional histology: a text and colour atlas. New York: Churchill Livingstone; 1993. p. 235–46.Google Scholar
  23. 23.
    Burris H. Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. Oncologist. 2004;9:10–5.PubMedGoogle Scholar
  24. 24.
    Capp A, Inostroza-Ponta M, Bill D, et al. Is there more than one proctitis syndrome? A revisitation using data from the TROG 96.01 trial. Radiother Oncol. 2009;90:400–7.PubMedGoogle Scholar
  25. 25.
    Carneiro-Filho B, Lima I, Araujo D, Cavalcante M, Carvalho G, Brito G, et al. Intestinal barrier function and secretion in methotrexate-induced rat intestinal mucositis. Dig Dis Sci. 2004;49:65–72.PubMedGoogle Scholar
  26. 26.
    Chabner B, Longo D. Cancer chemotherapy and biotherapy. Philadelphia: Lippincott-Raven; 1996.Google Scholar
  27. 27.
    Cobleigh M, Vogel C, Tripathy D, Robert N, et al. Multinational study of the efficacy and safety of the humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17:2639–48.PubMedGoogle Scholar
  28. 28.
    Damia G, D’Incalci M. Contemporary pre-clinical development of anticancer agents—what are the optimal preclinical models? Eur J Cancer. 2009;45(16):2768–81.PubMedGoogle Scholar
  29. 29.
    de Koning B, Dieren J, Lindenbergh-Kortleve D, van der Sluis M, Matsumoto T, Yamaguchi K, et al. Contributions of mucosal immune cells to methotrexate-induced mucositis. Int Immunol. 2006;18:941–9.PubMedGoogle Scholar
  30. 30.
    Di Lauro V, Murrone A, Bidoli E, Magri MD, Crivellari D, Veronesi A. Trastuzumab and vinorelbine as highly effective and safe therapy for HER-2-overexpressing metastatic breast cancer. A single institution experience. Tumori. 2008;94(4):464–8.PubMedGoogle Scholar
  31. 31.
    Elting L, Cooksley C, Chambers M, Cantor S, Manzullo E, Rubenstein E. The burdens of cancer therapy: clinical and economic outcomes of chemotherapy-induced mucositis. Cancer. 2003;98:1531–9.PubMedGoogle Scholar
  32. 32.
    Esteban E, Gonzalez de Sande L, Fernandez Y, Corral N, Fra J, Muniz I, et al. Prospective randomised phase II study of docetaxel versus paclitaxel administered weekly in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. Ann Oncol. 2003;14:1640–7.PubMedGoogle Scholar
  33. 33.
    Feher O, Martins S, Lima C, Salvajoli J, Kowalski L. Pilot trial of concurrent chemoradiotherapy with paclitaxel and conventional fractionated irradiation in advanced unresectable squamous cell carcinoma of the head and neck [abstract 1694J]. Prog/Proc Am Soc Clin Oncol. 2000;19:431a.Google Scholar
  34. 34.
    Figliolia S, Oliveira D, Pereira M, Lauris J, Mauricio A, Oliveira D, et al. Oral mucositis in acute lymphoblastic leukaemia: analysis of 169 paediatric patients. Oral Dis. 2008;14:761–6.PubMedGoogle Scholar
  35. 35.
    Fiochhi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology. 1998;115:182–205.Google Scholar
  36. 36.
    Fountzilas G, Tsavdaridis D, Kalogera-Fountzila A, Christodoulou C, Timotheadou E, Kalofonos C, et al. Weekly paclitaxel as first-line chemotherapy and trastuzumab in patients with advanced breast cancer. A Hellenic Cooperative Oncology Group phase II study. Ann Oncol. 2001;12:1545–51.PubMedGoogle Scholar
  37. 37.
    Gervaz P, Morel P, Vozenin-Brotons M. Molecular aspects of intestinal radiation-induced fibrosis. Curr Mol Med. 2009;9:273–80.PubMedGoogle Scholar
  38. 38.
    Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355(26):2733–43.PubMedGoogle Scholar
  39. 39.
    Gibson R, Bowen J, Alvarez E, Finnie J, Keefe D. Establishment of a single-dose irinotecan model of gastrointestinal mucositis. Chemotherapy. 2007;53:360–9.PubMedGoogle Scholar
  40. 40.
    Gibson R, Bowen J, Cummins A, Keefe D. Relationship between dose of methotrexate, apoptosis, p53/p21 expression and intestinal crypt proliferation in the rat. Clin Exp Med. 2005;4:188–95.PubMedGoogle Scholar
  41. 41.
    Gibson R, Keefe D, Thompson F, Clarke J, Goland G, Cummins A. Effect of interleukin-11 on ameliorating intestinal damage after methotrexate treatment of breast cancer in rats. Dig Dis Sci. 2002;47:2751–7.PubMedGoogle Scholar
  42. 42.
    Guardiola E, Peyrade F, Chaigneau L, Cupissol D, Tchiknavorian X, Bompas E, et al. Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer. Eur J Cancer. 2004;40:2071–6.PubMedGoogle Scholar
  43. 43.
    Hannum Y. Apoptosis and the dilemma of cancer chemotherapy. Blood. 1997;89:1845–53.Google Scholar
  44. 44.
    Hauer-Jensen M. Late radiation injury of the small intestine. Clinical, pathophysiologic and radiobiologic aspects. A review. Acta Oncol. 1990;29:401–15.PubMedGoogle Scholar
  45. 45.
    Hendry J, Potten C, Roberts N. The gastrointestinal syndrome and mucosal clonogenic cells: relationships between target cell sensitivities, LD50 and cell survival and their modification by antibiotics. Radiat Res. 1983;96:100–12.PubMedGoogle Scholar
  46. 46.
    Henson C. Chronic radiation proctitis: issues surrounding delayed bowel dysfunction post-pelvic radiotherapy and an update on medical treatment. Ther Adv Gastroenterol. 2010;3:359–65.Google Scholar
  47. 47.
    Hofheinz R, Wenz F, Post S, et al. Capecitabine (Cape) versus 5-fluorouracil (5-FU)-based (neo)adjuvant chemoradiotherapy (CRT) for locally advanced rectal cancer (LARC): long-term results of a randomized, phase III trial. ASCO Annual Meeting Abstract 3504; 2011.Google Scholar
  48. 48.
    Hortobagyi G, Frye D, Buzdar A, Ewer M, Fraschini G, Hug V, et al. Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma. Cancer. 1989;63:37–45.PubMedGoogle Scholar
  49. 49.
    Ikuno N, Soda H, Watanabe M, Oka M. Irinotecan (CPT-11) and characteristic changes in the mouse ileum and cecum. J Natl Cancer Inst. 1995;87:1876–983.PubMedGoogle Scholar
  50. 50.
    Kadoyama K, Miki I, Tamura T, Brown J, Sakaeda T, Okuno Y. Adverse event profiles of 5-Fluorouracil and capecitabine: data mining of the public version of the FDA adverse event reporting system, AERS, and reproducibility of clinical observations. Int J Med Sci. 2012;9:33–9.PubMedGoogle Scholar
  51. 51.
    Kakoei S, Haghdoost A, Rad M, Mohammadalizadeh S, Pourdamghan N, Nakhaei M, et al. Xerostomia after radiotherapy and its effects on quality of life in head and neck cancer patients. Arch Iran Med. 2012;15:214–8.PubMedGoogle Scholar
  52. 52.
    Keefe D. The effect of cytotoxic chemotherapy on the mucosa of the small intestine. Department of Medicine, University of Adelaide. PhD; 1998.Google Scholar
  53. 53.
    Keefe D. Chemotherapy for cancer causes apoptosis that precedes hypoplasia in crypts of the small intestine in humans. Gut. 2000;47:632–7.PubMedGoogle Scholar
  54. 54.
    Keefe D. Gastrointestinal mucositis: a new biological model. Support Care Cancer. 2004;12:6–9.PubMedGoogle Scholar
  55. 55.
    Keefe D. Mucositis and lung cancer. World Congress on Lung Cancer; 2009.Google Scholar
  56. 56.
    Keefe D, Bateman E. Tumor control versus adverse events with targeted anticancer therapies. Nat Rev Clin Oncol. 2011;9:98–109.PubMedGoogle Scholar
  57. 57.
    Keefe D, Gibson R. Mucosal injury from targeted anticancer therapy. Support Care Cancer. 2007;15:483–90.PubMedGoogle Scholar
  58. 58.
    Keefe D, Schubert M, Elting L, Sonis S, Epstein J, Raber-Durlacher J, et al. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer. 2007;109:820–31.PubMedGoogle Scholar
  59. 59.
    Kerr J, Winterford C, Harmon B. Apoptosis: its significant in cancer and cancer therapy. Cancer. 1994;73:2013–26.PubMedGoogle Scholar
  60. 60.
    Langberg C, Hauer-Jensen M, Sung C, Kane C. Expression of fibrogenic cytokines in rat small intestine after fractionated irradiation. Radiother Oncol. 1994;32:29–36.PubMedGoogle Scholar
  61. 61.
    Lima-Junior R, Figueiredo A, Freitas H, Melo M, Wong D, Leite C, et al. Involvement of nitric oxide on the pathogenesis of irinotecan-induced intestinal mucositis: role of cytokines on inducible nitric oxide synthase activation. Cancer Chemother Pharmacol. 2012;69:931–42.PubMedGoogle Scholar
  62. 62.
    Lockhart P, Sonis S. Relationship of oral complications to peripheral blood leukocytes and platelet counts in patients receiving cancer chemotherapy. Oral Surg Oral Med Oral Pathol. 1971;48:21–8.Google Scholar
  63. 63.
    Logan R, Gibson R, Bowen J, Stringer A, Sonis S, Keefe D. Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis. Cancer Chemother Pharmacol. 2008;62:33–41.PubMedGoogle Scholar
  64. 64.
    Logan R, Gibson R, Sonis S, Keefe D. Nuclear factor-kB (NFkB) and cyclooxygenase-2 expression in the oral mucosa following cancer chemotherapy. Oral Oncol. 2007;43:395–401.PubMedGoogle Scholar
  65. 65.
    Logan R, Stringer A, Bowen J, Gibson R, Sonis S, Keefe D. Serum levels of NFkappaB and pro-inflammatory cytokines following administration of mucotoxic drugs. Cancer Biol Ther. 2008;7:1139–45.PubMedGoogle Scholar
  66. 66.
    Logan R, Stringer A, Bowen J, Gibson R, Sonis S, Keefe D. Is the pathobiology of chemotherapy-induced alimentary tract mucositis influenced by the type of mucotoxic drug administered? Cancer Chemother Pharmacol. 2009;63:239–51.PubMedGoogle Scholar
  67. 67.
    Logan R, Stringer A, Bowen J, Yeoh A, Gibson R, Sonis S, et al. The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: pathobiology, animal models and cytotoxic drugs. Cancer Treat Rev. 2007;33:448–60.PubMedGoogle Scholar
  68. 68.
    Lutgens L, Blijlevens N, Deutz N, Donnelly J, Lambin P, De Pauw B. Monitoring myeloablative therapy-induced small bowel toxicity by serum citruilline concentration: a comparison with sugar permeability tests. Cancer. 2005;103:191–9.PubMedGoogle Scholar
  69. 69.
    Ma M, McLeod H. Lessons learned from the irinotecan metabolic pathway. Curr Med Chem. 2003;10:41–9.PubMedGoogle Scholar
  70. 70.
    Manzano M, Bueno P, Rueda R, Ramirez-Tortosa C, Prieto P, Lopez-Pedrosa J. Intestinal toxicity induced by 5-fluorouracil in pigs: a new preclinical model. Chemotherapy. 2007;53:344–55.PubMedGoogle Scholar
  71. 71.
    Marathe PH, Rodrigues AD. Examination of CYP3A and P-glycoprotein-mediated drug-drug interactions using animal models. Methods Mol Biol. 2010;596:385–403.PubMedGoogle Scholar
  72. 72.
    Martignoni M, Groothuis GM, de Kanter R. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol. 2006;2(6):875–94.PubMedGoogle Scholar
  73. 73.
    Martin M, van Saene H. The role of oral microorganisms in cancer therapy. Curr Opin Dent. 1992;2:81–4.PubMedGoogle Scholar
  74. 74.
    McBride W, Mason K, Withers H, Davis C. Effect of interleukin 1, inflammation, and surgery on the incidence of adhesion formation and death after abdominal irradiation in mice. Cancer Res. 1989;49:169–73.PubMedGoogle Scholar
  75. 75.
    Michael H, Gordon I, Wojciech P. Histology: a text and atlas. Philadelphia: Lippincott Williams & Wilkins; 2003.Google Scholar
  76. 76.
    Moy B, Goss P. Lapatinib-associated toxicity and practical management recommendations. Oncologist. 2007;12:756–65.PubMedGoogle Scholar
  77. 77.
    Murphy B. Clinical and economic consequences of mucositis induced by chemotherapy and/or radiation therapy. J Support Oncol. 2007;5:13–21.PubMedGoogle Scholar
  78. 78.
    Nakao T, Kurita N, Komatsu M, Yoshikawa K, Iwata T, Utusnomiya T, et al. Irinotecan injures tight junction and causes bacterial translocation in rat. J Surg Res. 2010;173:341–7.PubMedGoogle Scholar
  79. 79.
    Napenas J, Brennan M, Coleman S, Kent M, Noll J, Frenette G, et al. Molecular methodology to assess the impact of cancer chemotherapy on the oral bacterial flora: a pilot study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;109:554–60.PubMedGoogle Scholar
  80. 80.
    Orga P, Mestecky J, Lamm M, Strober W, Bienenstock J, McGhee J. Mucosal immunology. San Diego: Academic; 1994.Google Scholar
  81. 81.
    Palumbo A, Bringhen S, Bruno B, Falcone A, Liberati A, Grasso M, et al. Melphalan 200 mg/m2 versus melphalan 100 mg/m2 in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study. Blood. 2010;115:1873–9.PubMedGoogle Scholar
  82. 82.
    Paolo A, Danesi R, Falcone A, Cionini L, Vannozzi F, Masi G, et al. Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients. Ann Oncol. 2001;12:1301–6.PubMedGoogle Scholar
  83. 83.
    Papaconstantinou H, Xie C, Zhang W, Andsari N, Hellmich M, Townsent C, et al. The role of caspases in methotrexate-induced gastrointestinal toxicity. Surgery. 2001;130:859–65.PubMedGoogle Scholar
  84. 84.
    Papaconstantinou H, Xie C, Zhang W, Ansari N, Hellmich M, Townsend C, et al. The role of caspaces in methotrexate-induced gastrointestinal toxicity. Surgery. 2001;130:859–65.PubMedGoogle Scholar
  85. 85.
    Paris F, Fuks Z, Kang A, Capodieci P, Juan G, Ehleiter D, et al. Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science. 2001;293:293–7.PubMedGoogle Scholar
  86. 86.
    Pegram M, Ngo D. Application and potential limitations of animal models utilized in the development of trastuzumab (Herceptin): a case study. Adv Drug Deliv Rev. 2006;58(5–6):723–34.PubMedGoogle Scholar
  87. 87.
    Peterson D, Keefe D, Sonis S. New frontiers in mucositis. ASCO Educational Book, ASCO; 2012.Google Scholar
  88. 88.
    Plosker G, Keam S. Trastuzumab: a review of its use in the management of HER2-positive metastatic and early stage breast cancer. Drugs. 2006;66:449–75.PubMedGoogle Scholar
  89. 89.
    Potten C, Booth C, Pritchard D. The intestinal epithelial stem cell: the mucosal governor. Int J Exp Pathol. 1997;78:219–43.PubMedGoogle Scholar
  90. 90.
    Potten C, Wilson J, Booth C. Regulation and significance of apoptosis in the stem cells of the gastrointestinal epithelium. Stem Cells. 1997;15:82–93.PubMedGoogle Scholar
  91. 91.
    Prisciandaro L, Geier M, Butler R, Cummins A, Howarth G. Probiotic factors partially improve parameters of 5-fluorouracil-induced intestinal mucositis in rats. Cancer Biol Ther. 2011;11:671–7.PubMedGoogle Scholar
  92. 92.
    Quarmby S, Hunter R, Kumar S. Irradiation induced expression of CD31, ICAM-1 and VCAM-1 in human microvascular endothelial cells. Anticancer Res. 2000;20:3375.PubMedGoogle Scholar
  93. 93.
    Ridwelski K, Gebauer T, Fahlke J, Kroning H, Kettner E, Meyer F, et al. Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer. Ann Oncol. 2001;12:47–51.PubMedGoogle Scholar
  94. 94.
    Roche A, Bognel J, Bognel C, Bernier J. Correlation between the histological changes and glucose intestinal absorption following a single dose of 5-fluorouracil. Digestion. 1970;3:195–212.PubMedGoogle Scholar
  95. 95.
    Roseth A. Determination of faecal calprotectin, a novel marker of organic gastrointestinal disorders. Dig Liver Dis. 2003;35:607–9.PubMedGoogle Scholar
  96. 96.
    Rothenberg M, Eckardt J, Kuhn J, Burris H, Nelson J, Hilsenbeck S, et al. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol. 1996;14:1128–35.PubMedGoogle Scholar
  97. 97.
    Ruescher T, Sodeifi A, Scrivani S, Kaban L, Sonis S. The impact of mucositis on alpha-hemolytic streptococcal infection in patients undergoing autologous bone marrow transplantation for hematologic malignancies. Cancer. 1998;82:2275–81.PubMedGoogle Scholar
  98. 98.
    Ruiz M, Salvador J, Bayo J, Lomas M, Moreno A, Valero M, et al. Phase-II study of weekly schedule of trastuzumab, paclitaxel, and carboplatin followed by a week off every 28 days for HER2+ metastatic breast cancer. Cancer Chemother Pharmacol. 2008;62:1085–90.PubMedGoogle Scholar
  99. 99.
    Sawaki M, Ito Y, Tada K, Mizunuma N, Takahashi S, Horikoshi N, et al. Efficacy and safety of trastuzumab as a single agent in heavily pretreated patients with HER-2/neu-overexpressing metastatic breast cancer. Tumori. 2004;90(1):40–3.PubMedGoogle Scholar
  100. 100.
    Scrimger R, Kanji A, Parliament M, Warkentin H, Field C, Jha N, et al. Correlation between saliva production and quality of life measurements in head and neck cancer patients treated with intensity-modulated radiotherapy. Am J Clin Oncol. 2007;30:271–7.PubMedGoogle Scholar
  101. 101.
    Shao Z, Tang Z, Yan C, Jiang Y, Ma R, Liu Z, et al. Effects of intensity-modulated radiotherapy on human oral microflora. J Radiat Res. 2011;52:834–9.PubMedGoogle Scholar
  102. 102.
    Small M, Cavanagh R, Gottlieb L, Colon P, Zamcheck N. The effect of aminopterin on the absorption of xylose from the rat small intestine. Am J Dig Dis. 1959;4:700–5.PubMedGoogle Scholar
  103. 103.
    Soga Y, Maeda Y, Ishimaru F, Tanimoto M, Maeda H, Nishimura F, et al. Bacterial substitution of coagulase-negative staphylococci for streptococci on the oral mucosa after hematopoietic cell transplantation. Support Care Cancer. 2011;19:995–1000.PubMedGoogle Scholar
  104. 104.
    Sonis A, Sonis S. Oral complications of cancer therapy in pediatric patients. J Pedodot. 1979;3:12–6.Google Scholar
  105. 105.
    Sonis S. The biologic role for nuclear factor-kappaB in disease and its potential involvement in mucosal injury associated with anti-neoplastic therapy. Crit Rev Oral Biol Med. 2002;13:380–9.PubMedGoogle Scholar
  106. 106.
    Sonis S. A biological approach to mucositis. J Support Oncol. 2004;2:21–32.PubMedGoogle Scholar
  107. 107.
    Sonis S. The pathobiology of mucositis. Nat Rev Cancer. 2004;4:277–84.PubMedGoogle Scholar
  108. 108.
    Sonis S, et al. Prevention of chemotherapy-induced ulcerative mucositis by transforming growth factor Beta-3. Cancer Res. 1994;54:1135–8.PubMedGoogle Scholar
  109. 109.
    Sonis S, Costa J, Evitts S, Lindquist L, Nicholson M. Effect of epidermal growth factor on ulcerative mucositis in hamsters that receive chemotherapy. Oral Surg Oral Med Oral Pathol. 1992;74:749–55.PubMedGoogle Scholar
  110. 110.
    Sonis S, Costa J, Evitts S, Lindquist L, Nicolson M. Effect of epidermal growth factor on ulcerative mucositis in hamsters that receive cancer chemotherapy. Oral Surg Oral Med Oral Pathol. 1992;74:749–55.PubMedGoogle Scholar
  111. 111.
    Sonis S, Elting L, Keefe D, Peterson D, Schubert M. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer. 2004;100:1995–2025.PubMedGoogle Scholar
  112. 112.
    Sonis S, Linquist L, VanVugt A, Stewart A, Stam K, Qu G, et al. Prevention of chemotherapy-induced ulcerative mucositis by transforming growth factor-beta3. Cancer Res. 1994;54:1135–8.PubMedGoogle Scholar
  113. 113.
    Sonis S, O’Donnell K, Popat R, Bragdon C, Phelan S, Cocks D, et al. The relationship between mucosal cyclooxygenase-2 (COX-2) expression and experimental radiation-induced mucositis. Oral Oncol. 2004;40:170–6.PubMedGoogle Scholar
  114. 114.
    Sonis S, Peterson R, Edwards L, Lucey C, Wang L, Mason L, et al. Defining mechanisms of action of interleukin-11 on the progression of radiation-induced oral mucositis in hamsters. Oral Oncol. 2000;36:373–81.PubMedGoogle Scholar
  115. 115.
    Sonis S, Scherer J, Phelan S, Lucey C, Barron J, O’Donnell K, et al. The gene expression sequence of radiated mucosa in an animal mucositis model. Cell Prolif. 2002;35:s92–102.Google Scholar
  116. 116.
    Sonis S, Shklar T, Jenson J, Florine D. An animal model for mucositis induced by cancer chemotherapy. Oral Surg Oral Med Oral Pathol. 1990;69:437–43.PubMedGoogle Scholar
  117. 117.
    Sonis S, Tracey C, Shklar G, Jenson J, Florine D. An animal model for mucositis induced by cancer chemotherapy. Oral Surg Oral Med Oral Pathol. 1990;69:437–43.PubMedGoogle Scholar
  118. 118.
    Sonis S, Treister N, Chawla S, Demetri G, Haluska F. Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients. Cancer. 2010;116:210–5.PubMedGoogle Scholar
  119. 119.
    Squier CA, Hill MW. Oral mucosa. In: Ten Cate AR, editor. Oral histology development, structure and function. St Louis: Mosby-Year Book Inc; 1994. p. 389–431.Google Scholar
  120. 120.
    Stringer A, Gibson R, Bowen J, Ashton K, Logan R, Al-Dasooqi N, et al. Irinotecan-induced mucositis manifesting as diarrhoea corresponds with an amended intestinal flora and mucin profile. Int J Exp Pathol. 2009;90:489–99.PubMedGoogle Scholar
  121. 121.
    Stringer A, Gibson R, Bowen J, Keefe D. Chemotherapy-induced changes to microflora: evidence and implications of change. Curr Drug Metab. 2009;10:79–83.PubMedGoogle Scholar
  122. 122.
    Stringer A, Gibson R, Logan R, Bowen J, Yeoh A, Burns J, et al. Chemotherapy-induced diarrhea is associated with changes in the luminal environment in the DA rat. Exp Biol Med. 2007;232:96–106.Google Scholar
  123. 123.
    Stringer A, Gibson R, Logan R, Bowen J, Yeoh A, Keefe D. Faecal microflora and β-glucuronidase expression are altered in an irinotecan-induced diarrhoea model in rats. Cancer Biol Ther. 2008;7:1919–25.PubMedGoogle Scholar
  124. 124.
    Stringer A, Gibson R, Logan R, Bowen J, Yeoh A, Keefe D. Gastrointestinal microflora and mucins play a role in the development of 5-Fluorouracil-induced gastrointestinal mucositis in rats. Exp Biol Med. 2009;234:430–41.Google Scholar
  125. 125.
    Takasuna K, Hirohashi M, Kato M, et al. Involvement of Beta-Glucuronidase in intestinal microflora in the intestinal toxicity of antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res. 1996;56:3752–7.PubMedGoogle Scholar
  126. 126.
    Toi M, Iwata H, Fujiwara Y, Ito Y, Nakamura S, Tokuda Y, et al. Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies. Br J Cancer. 2009;101(10):1676–82.PubMedGoogle Scholar
  127. 127.
    Tortora GJ, Grabowski SR. Principles of anatomy and physiology. New York: HarperCollins; 1993.Google Scholar
  128. 128.
    van der Velden W, Donnelly J, Blijlevens N. Lymphocyte subsets, granulocyte-colony-stimulating factor responsiveness and post-stem cell transplantation infections: mucositis is the underestimated confounder? Cytotherapy. 2012;14:381–3.PubMedGoogle Scholar
  129. 129.
    van Vliet M, Harmsen H, de Bont E, Tissing W. The role of intestinal microbiota in the development and severity of chemotherapy-induced mucositis. PLoS Pathog. 2010;6(5):e1000879.PubMedGoogle Scholar
  130. 130.
    Verburg M, Renes I, Meijer H, Tamininau J, Buller H, Einerhand A, et al. Selective sparing of goblet cells and paneth cells in the intestine of methotrexate-treated rats. Am J Physiol. 2000;279:G1037–47.Google Scholar
  131. 131.
    Wang R, Iganej S, Cosmatos H, Latino F, Kagan R. Pilot trial of concurrent low-dose weekly paclitaxel and radiotherapy in patients with advanced squamous cell carcinoma of the head and neck (SCCHN) [abstract 1685]. Prog/Proc Am Soc Clin Oncol. 2000;19:426a.Google Scholar
  132. 132.
    Weichselbaum R, Hallahan D, Fuks Z, Kufe D. Radiation induction of immediate early genes: effectors of the radiation-stress response. Int J Radiat Oncol Biol Phys. 1994;30:229.PubMedGoogle Scholar
  133. 133.
    Wisplinghoff H, Seifert H, Wenzel R, Edmond M. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis. 2003;36:1103–10.PubMedGoogle Scholar
  134. 134.
    Wright NA. Stem cell repertoire in the intestine. In: Potten CS, editor. Stem cells. London: Academic; 1997. p. 315–30.Google Scholar
  135. 135.
    Wu X, Chen P, Sonis S, Lingen M, Berger A, Toback F. A novel peptide to treat oral mucositis blocks endothelial and epithelial cell apoptosis. Int J Radiat Oncol Biol Phys. 2012;83:e409–15.PubMedGoogle Scholar
  136. 136.
    Wurth M, Musacchila X. Mechlorethamine effects on intestinal absorption in vitro and on cell proliferation. Am J Physiol. 1973;225:73–80.PubMedGoogle Scholar
  137. 137.
    Yeoh A, Bowen J, Gibson R, Keefe D. Nuclear factor kappaB (NFkappaB) and cyclooxygenase-2 (Cox-2) expression in the irradiated colorectum is associated with subsequent histopathological changes. Int J Radiat Oncol Biol Phys. 2005;63:1295–303.PubMedGoogle Scholar
  138. 138.
    Zhao J, Huang L, Belmar N, Buelow R, Fong T. Oral RDP58 allows CPT-11 dose intensification for enhanced tumor response by decreasing gastrointestinal toxicity. Clin Cancer Res. 2004;10:2851–9.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Noor Al-Dasooqi
    • 1
  • Dorothy M. Keefe
    • 2
  • Dorothy M. Keefe
    • 3
  • Stephen T. Sonis
    • 4
  1. 1.Department of MedicineUniversity of AdelaideAdelaideAustralia
  2. 2.University of AdelaideAdelaideAustralia
  3. 3.Sansom Institute for Health ResearchUniversity of South AustraliaAdelaideAustralia
  4. 4.Brigham and Women’s HospitalBostonUSA

Personalised recommendations